Akebia Therapeutics' Series A - II Round

Akebia Therapeutics raised a round of funding on July 13, 2009.

Akebia Therapeutics is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an inv…

Articles about Akebia Therapeutics' Series A - II Round: